MEK inhibitor cobimetinib rescues a dRaf mutant lethal phenotype in Drosophila melanogaster. Issue 9 (19th August 2019)

• Record Type: Journal Article
• Authors: Pfeifle, Isabelle; Bohnekamp, Jens; Volkhardt, Anna; Kirsten, Holger; Rohwedder, Astrid; Thum, Andreas; Magin, Thomas M.; Kunz, Manfred
• Is Part Of: Experimental dermatology. Volume 28:Issue 9(2019)
• Page Start: 1079
• Page End: 1082
• Publication Date: 2019-08-19
• Subjects: BRAF -- genetics -- molecular biology -- small‐molecule inhibitors -- tumor; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.14010
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: Since Drosophila melanogaster has proven to be a useful model system to study phenotypes of oncogenic mutations and to identify new anti‐cancer drugs, we generated human BRAF V600E homologous dRaf mutant ( dRaf A572E ) Drosophila melanogaster strains to use these for characterisation of mutant phenotypes and exploit these phenotypes for drug testing. For mutant gene expression, the GAL4/UAS expression system was used. dRaf A572E was expressed tissue‐specific in the eye, epidermis, heart, wings, secretory glands and in the whole animal. Expression of dRaf A572E under the control of an eye‐specific driver led to semi‐lethality and a rough eye phenotype. The vast majority of other tissue‐specific and ubiquitous drivers led to a lethal phenotype only. The rough eye phenotype was used to test BRAF inhibitor vemurafenib and MEK1/2 inhibitor cobimetinib. There was no phenotype rescue by this treatment. However, a significant rescue of the lethal phenotype was observed under a gut‐specific driver. Here, MEK1/2 inhibitor cobimetinib rescued Drosophila larvae to reach pupal stage in 37% of cases as compared to 1% in control experiments. Taken together, the BRAF V600E homolog dRaf A572E exerts mostly lethal effects in Drosophila . Gut‐specific dRaf A572E expression might in future be developed further for drug testing.